Volume 85, Issue 7 pp. 1240-1247
Valvular and Structural Heart Diseases

N-terminal pro-B-type natriuretic peptide-ratio predicts mortality after transcatheter aortic valve replacement

Barbara E. Stähli MD

Barbara E. Stähli MD

Department of Cardiology, University Heart Center, Zurich, Switzerlan

Barbara E. Stähli and Cathérine Gebhard contributed equally to this work.

Search for more papers by this author
Cathérine Gebhard MD

Cathérine Gebhard MD

Department of Cardiology, University Heart Center, Zurich, Switzerlan

Barbara E. Stähli and Cathérine Gebhard contributed equally to this work.

Search for more papers by this author
Lanja Saleh PhD

Lanja Saleh PhD

Institute of Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland

Search for more papers by this author
Volkmar Falk MD

Volkmar Falk MD

Departement of Cardiovascular Surgery, University Heart Center, Zurich, Switzerlan

Search for more papers by this author
Ulf Landmesser MD

Ulf Landmesser MD

Department of Cardiology, University Heart Center, Zurich, Switzerlan

Search for more papers by this author
Fabian Nietlispach MD, PhD

Fabian Nietlispach MD, PhD

Department of Cardiology, University Heart Center, Zurich, Switzerlan

Search for more papers by this author
Francesco Maisano MD

Francesco Maisano MD

Departement of Cardiovascular Surgery, University Heart Center, Zurich, Switzerlan

Search for more papers by this author
Thomas F. Lüscher MD

Thomas F. Lüscher MD

Department of Cardiology, University Heart Center, Zurich, Switzerlan

Search for more papers by this author
Willibald Maier MD

Willibald Maier MD

Department of Cardiology, University Heart Center, Zurich, Switzerlan

Search for more papers by this author
Ronald K. Binder MD

Corresponding Author

Ronald K. Binder MD

Department of Cardiology, University Heart Center, Zurich, Switzerlan

Correspondence to: Ronald K. Binder, MD, Department of Cardiology, University Heart Center Zurich, University Hospital Zürich, Rämistrasse 100, 8091 Zürich, Switzerland. E-mail: [email protected]Search for more papers by this author
First published: 15 December 2014
Citations: 26

Conflict of interest: Dr Nietlispach is a proctor for Edwards Lifesciences, Dr. Binder is a consultant to Edwards Lifesciences. All other authors have no conflicts of interest to declare.

Abstract

Objectives

We studied the prognostic value of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP)-ratio, which is independent of individual cutoff levels, in predicting mortality in patients undergoing transcatheter aortic valve replacement (TAVR). Background: Elevated levels of natriuretic peptides are associated with adverse outcomes across a wide spectrum of cardiovascular diseases. However, cutoff values differ according to age, gender, and body weight. Methods: 244 TAVR patients with preprocedural NT-proBNP levels were analyzed, and the predictive value of NT-proBNP-ratio (measured NT-proBNP/maximal normal NT-proBNP values specific for age and gender) on all-cause-mortality was assessed in a multivariate model. Results: Median NT-proBNP-ratio was 4.2 [IQR 1.8–9.7]. All-cause mortality at 30 days was 3.4% in patients with less than median NT-proBNP-ratio, and 14.0% in patients with more than median NT-proBNP-ratio (P = 0.02). All-cause mortality at 1 year was 8.5% in patients with less than median NT-proBNP-ratio, and 32.1% in those with more than median NT-proBNP-ratio (P = 0.001). Cumulative survival declined with increasing quartiles of NT-proBNP-ratio (log rank P = 0.001). All patients with a NT-proBNP-ratio below 1.5 survived at 1-year follow-up. In ROC analysis, NT-proBNP-ratio significantly predicted 30-day (AUC = 0.72; P = 0.002) and 1-year all-cause mortality (AUC = 0.72; P < 0.001). By multivariate Cox regression analysis, NT-proBNP-ratio, chronic obstructive pulmonary disease, and serum creatinine were the only independent predictors of all-cause mortality. Conclusions: Elevated NT-proBNP-ratio was associated with increased short- and long-term mortality after TAVR, and independently predicted all-cause mortality. NT-proBNP-ratio should be considered in the risk stratification of patients undergoing TAVR. © 2015 Wiley Periodicals, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.